Discovering new treatments for cancer-associated cognitive impairment

Cognitive impairment is extremely common among cancer patients and survivors. The Laboratory of ImmunoPsychiatry has determined that the cancer itself contributes to this using animal models of breast cancer, which may be prevented by the use of anti-inflammatory drugs. We are now trying to determine the precise biological changes that occur in the brains of cancer patients that lead to long-term cognitive impairment and identify novel treatment strategies that can be tested in clinical populations from diagnosis through to the end of treatment.

Expertise & facilities